Patent Assignment
Reel/Frame 015044/0873
Change of Name
Recorded: 2004-08-06
Pages: 7
Assignor
IDEC PHARMACEUTICALS CORPORATION
Executed: 2003-11-12
Assignee
BIOGEN IDEC INC.
3030 CALLAN ROAD, SAN DIEGO, CALIFORNIA, 92121
Covered Properties
(134)
Anti-Idiotype Antibodies to Human Melanoma-Associated Proteoglycan Antigen
Application:
07/431,426 →
Induction of Cytotoxic T-Lymphocyte Responses
Application:
07/735,069 →
Chimeric Antibodies for Human Therapy
Application:
07/856,281 →
Recombinant Antibodies for Human Therapy
Application:
07/912,292 →
Impaired Dominant Selectable Marker Sequence for Enhancement of Expression of Co-Linked Gene Product and Expression Vector Systems Comprising Same
Application:
07/977,691 →
Induction of Cytotoxic T-Lymphocyte Responses
Application:
08/476,674 →
Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens
Application:
08/746,361 →
Synergistic Composition and Methods for Treatingneoplastic or Cancerous Growths and for Restoring or Boosting Hematopoiesis
Application:
08/933,359 →
Recombinant Antibodies for Human Therapy
Application:
09/082,472 →
Method for Producing Human Antibodies in Scid Mice Which Uses Dendritic Cells Pulsed with Antigen-Antibody Complexes and Antigen-Antibody Complexes as Immunizing Agents
Application:
09/149,479 →
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
Application:
09/615,796 →
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
Application:
09/834,933 →
Publication:
US 2001/0018041
Recombinant antibodies for human therapy
Application:
09/850,165 →
Publication:
US 2002/0150580
Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
Application:
09/877,065 →
Publication:
US 2002/0051990
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
Application:
09/971,631 →
Publication:
US 2003/0036113
Method for Producing Human Antibodies in Scid Mice Which Uses Dendritic Cells Pulsed with Antigen-Antibody Complexes and Antigen-Antibody Complexes as Immunizing Agents
Application:
60/057,831 →
Tumor Antigen-Specific Antibody-GP39 Chimeric Protein Constructs
Application:
60/109,607 →
New Clinical Parameters for Determining Hematologic Toxicity Prior to Radioimmunotherapy
Application:
60/148,288 →
Method for praparing anti-MIF antibodies
Application:
60/185,390 →
Two monoclonal antibodies that bind phosphatidyl serine and a method of killing tumor cells
Application:
60/189,050 →
Combined use of anti-cytokine antibodies and anti-CD20 for the treatment of B-cell lymphoma
Application:
60/193,467 →
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
Application:
60/199,365 →
Non-agonistric antibodies to human gp39, compositions containing and therapeutic use thereof
Application:
60/209,584 →
Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
Application:
60/210,451 →
Treatment of b-cell associated diseases such as malignancies and autommune diseases using anti-cd20 antibody/radiolabled anti-cd22 antibody combination
Application:
60/212,668 →
Treatment of B cell malignancies using antoi-CD40L antibodies in combination with anti-CD20 antibodies and/or chemtherapetics and radiotherapy
Application:
60/217,706 →
Combination therapy for treatment of autoimmune diseases comprising CD40L antagonist and antibodies to B7,CD19,CD20,CD22,CD23
Application:
60/233,607 →
Method for preparing anti-mif antibodies
Application:
60/233,625 →
Variant lgg3 rituxan and therapeutic use thereof
Application:
60/241,022 →
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
Application:
60/257,147 →
Modified antibodies and methods of use
Application:
60/264,318 →
Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcyRIII
Application:
60/280,139 →
Inhibition of apoptosis process and improvement of cell performance
Application:
60/303,813 →
Anti CD 80 and rituximab combination therapy of B-cell lymphoma
Application:
60/331,187 →
Polycistronic expression of antibodies
Application:
60/331,481 →
Genes correlated to ovarian cancer and their use in developing novel therapeutics
Application:
60/341,860 →
Prostate specific genes and the use thereof in design or therapeutics
Application:
60/357,140 →
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
Application:
60/367,727 →
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
Application:
60/381,328 →
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
Application:
60/386,747 →
Genes correlated to ovarian cancer and their use in developing novel therapeutics
Application:
60/386,748 →
Prostate specific genes and the use thereof in design of therapeutics
Application:
60/386,759 →
Buffered formulations for concentrating antibodies
Application:
60/390,191 →
Prostate specific genes and the use thereof in design of therapeutics
Application:
60/396,082 →
Genes correlated to ovarian cancer and their use in developing novel therapeutics
Application:
60/396,141 →
Polycistronic expression of antibodies
Application:
60/400,687 →
Genes correlated to ovarian cancer and their use in developing novel therapeutics
Application:
60/405,319 →
Method of purifying antibodies by simulated moving bed chromatography
Application:
60/410,506 →
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
Application:
60/427,564 →
Genes correlated to ovarian cancer and their use in developing novel therapeutics
Application:
60/428,274 →
Thiol-mediated drug attachment to targeting peptides
Application:
60/452,928 →
Production of Tetravalent Antibodies
Patent:
6,897,044 →
Application:
09/238,741 →
Radiolabeling Kit and Binding Assay
Application:
09/259,337 →
Publication:
US 2002/0102208
Kit for Radiolabeling Ligands with Yttrium-90
Application:
09/259,338 →
Treatment of B Cell Malignancies Using Anti-CD40L Antibodies in Combination with Anti-CD20 Antibodies and/or Chemotherapeutics and Radiotherapy
Application:
09/435,992 →
Treating Intestinal Inflammation with Anti-CD80 Antibodies That Do Not Inhbit CD80 Binding to Ctla-4
Patent:
7,175,847 →
Application:
09/576,424 →
Recombinant Anti-CD4 Antibodies for Human Therapy
Patent:
7,452,534 →
Application:
09/612,914 →
Kit for Radiolabeling Ligands with Yttrium-90
Patent:
6,994,840 →
Application:
09/628,186 →
Methods for Treating B Cell Lymphoma Using CD80-Specific Antibodies
Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
Application:
09/772,938 →
Publication:
US 2002/0006404
Method for preparing anti-MIF antibodies
Application:
09/791,551 →
Publication:
US 2003/0235584
Method for Producing Human Antibodies in Scid Mice Which Uses Dendritic Cells Pulsed with Antigen-Antibody Complexes and Antigen-Antibody Complexes as Immunizing Agents
Antibodies that bind phosphatidyl serine and a method of their use
Application:
09/805,217 →
Publication:
US 2002/0025319
Combined Use of Anti-Cytokine Antibodies or Antagonists and Anti-CD20 for Treatment of B Cell Lymphoma
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
Application:
09/840,872 →
Publication:
US 2002/0009444
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
Application:
09/853,580 →
Publication:
US 2001/0018054
Synergistic Composition and Methods for Treating Neoplastic or Cancerous Growths and for Restoring or Boosting Hematopoiesis
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
Application:
09/855,717 →
Publication:
US 2002/0028178
Tumor antigen- specific antibody- gp39 chimeric protein constructs
Application:
09/856,534 →
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
Application:
09/874,141 →
Publication:
US 2003/0012781
Treatment of B-Cell Associated Diseases Such as Malignances and Autoimmune Diseases Using a Cold Anti-CD20 Antibody/Radiolabeled Anti-CD22 Antibody Combination
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
Application:
09/954,274 →
Publication:
US 2002/0058029
Variant IgG3 Rituxan and therapeutic use thereof
Application:
09/982,849 →
Publication:
US 2002/0128448
Use of CD23 antagonists for the treatment of neoplastic disorders
Application:
09/985,646 →
Publication:
US 2002/0159996
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
Application:
09/986,174 →
Publication:
US 2002/0193569
Treatment of B Cell Lymphoma Using Anti-CD80 Antibodies That Do Not Inhibit the Binding of CD80 to Ctla-4
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
Application:
10/096,963 →
Publication:
US 2003/0180292
Novel Method for Integrating Genes at Specific Sites in Mammalian Cells via Homologous Recombination and Vectors for Accomplishing the Same
Recombinant antibodies coexpressed with GnTIII
Application:
10/113,929 →
Publication:
US 2003/0003097
Humanized Antibodies to Human GP39, Compositions Containing and Therapeutic Use Thereof
Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody
Inhibition of Apoptosis Process and Improvement of Cell Performance
New Clinical Parameters for Deteriming Hematologic Toxicity Prior to Radioimmunotherapy
Recombinant Anti-CD4 Antibodies for Human Therapy
Use of CD23 antagonists for the treatment of neoplastic disorders
Application:
10/241,832 →
Publication:
US 2003/0211107
Immunoregulatory antibodies and uses thereof
Application:
10/241,836 →
Publication:
US 2003/0103971
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
Application:
10/291,532 →
Publication:
US 2003/0180290
Polycistronic expression of antibodies
Application:
10/295,823 →
Publication:
US 2003/0157641
Prostate specific genes and the use thereof in design or therapeutics
Application:
10/367,978 →
Publication:
US 2003/0235533
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
Application:
10/384,356 →
Publication:
US 2004/0005323
Method of Purifying Polypeptides by Simulated Moving Bed Chromatography
Induction of cytotoxic T-lymphocyte responses
Application:
10/743,398 →
Publication:
US 2004/0197331
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
Application:
10/743,739 →
Publication:
US 2004/0137014
Treatment of Patients Having Non-Hodgkins Lymphoma with Bone Marrow Involvement with Anti-CD20 Antibodies
Application:
60/148,287 →
Use of depth filtration and continuous centrifugation to clarify cell samples
Application:
60/479,910 →
Lectin affinity purification and identification of proteins of vascular tissue associated with a disease or disorder
Application:
60/510,552 →
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
Application:
10/703,669 →
Publication:
US 2005/0112060
Thiol-mediated drug attachment to targeting peptides
Application:
10/796,158 →
Publication:
US 2005/0118099
Use of Depth Filtration in Series with Continuous Centrifugation to Clarify Mammalian Cell Cultures
Tag-72 Specific CH2 Domain Deleted Antibodies
Anti-Idiotype Antibodies to Human Melanoma-Associated Proteoglycan Antigen
Patent:
5,270,202 →
Application:
07/680,808 →
Induction of Cytotoxic T-Lymphocyte Responses
Patent:
5,585,103 →
Application:
07/919,787 →
Impaired Dominant Selectable Marker Sequence and Intronic Insertion Strategies for Enhancement of Expression of Gene Product and Expression Vector Systems Comprising Same
Patent:
5,648,267 →
Application:
08/147,696 →
Recombinant Antibodies for Human Therapy
Patent:
5,658,570 →
Application:
08/379,072 →
Recombinant Antibodies for Human Therapy
Patent:
5,681,722 →
Application:
08/478,039 →
Recombinant Antibodies for Human Therapy
Patent:
5,693,780 →
Application:
08/481,869 →
Induction of Cytotoxic T-Lymphocyte Responses
Patent:
5,695,770 →
Application:
08/472,311 →
Induction of Cytotoxic T-Lymphocyte Responses
Patent:
5,709,860 →
Application:
08/351,001 →
Impaired Dominant Selectable Marker Sequence and Intronic Insertion Strategies for Enhancement of Expression of Gene Product and Expression Vector Systems Comprising Same
Patent:
5,733,779 →
Application:
08/484,334 →
Recombinant Antibodies for Human Therapy
Patent:
5,750,105 →
Application:
08/476,349 →
Recombinant Antibodies for Human Therapy
Patent:
5,756,096 →
Application:
08/476,237 →
Neutralizing High Affinity Human Monoclonal Antibodies Specific to Rsv F-Protein and Methods for Their Manufacture and Therapeutic Use Thereof
Patent:
5,811,524 →
Application:
08/488,376 →
Novel Method for Integrating Genes at Specific Sites in Mammalian Cells via Homologous Recombination and Vectors for Accomplishing the Same
Patent:
5,830,698 →
Application:
08/819,866 →
Neutralizing High Affinity Human Monoclonal Antibodies Specific to Rsv F-Protein and Methods for Their Manufacture and Therapeutic Use Thereof
Patent:
5,840,298 →
Application:
08/634,223 →
Neutralizing High Affinity Human Monoclonal Antibodies Specific to Rsv F-Protein and Methods for Their Manufacture and Therapeutic Use Thereof
Patent:
5,866,125 →
Application:
08/634,224 →
Neutralizing High Affinity Human Monoclonal Antibodies Specific to Rsv F-Protein and Methods for Their Manufacture and Therapeutic Use Thereof
Patent:
5,939,068 →
Application:
08/634,400 →
Neutralizing High Affinity Human Monoclonal Antibodies Specific to Rsv F-Protein and Methods for Their Manufacture and Therapeutic Use Thereof
Patent:
5,955,364 →
Application:
08/635,878 →
Method for Integrating Genes at Specific Sites in Mammalian Cells via Homologous Recombination and Vectors for Accomplishing the Same
Patent:
5,998,144 →
Application:
09/023,715 →
Humanized Antibodies to Human GP39, Compositions Containing and Therapeutic Use Thereof
Patent:
6,001,358 →
Application:
08/554,840 →
Impaired Dominant Selectable Marker Sequence and Intronic Insertion Strategies for Enhancement of Expression of Gene Product and Expression Vector Systems Comprising Same
Patent:
6,017,733 →
Application:
09/013,092 →
Human B7.1-Specific Primatized Antibodies and Transfectomas Expressing Said Antibodies
Patent:
6,113,898 →
Application:
08/487,550 →
Recombinant Anti-CD4 Antibodies for Human Therapy
Patent:
6,136,310 →
Application:
08/523,894 →
Impaired Dominant Selectable Marker Sequence and Intronic Insertion Strategies for Enhancement of Expression of Gene Product and Expession Vector Systems Comprising Same
Patent:
6,159,730 →
Application:
09/280,999 →
Induction of Cytotoxic T-Lymphocyte Responses
Patent:
6,197,311 →
Application:
09/024,220 →
Regioselective Synthesis of Dtpa Derivatives
Patent:
6,207,858 →
Application:
09/261,207 →
Induction of Cytotoxic T-Lymphocyte Responses
Patent:
6,270,769 →
Application:
08/449,728 →
Electrochemiluminescent Assays for Eukaryotic Cells
Patent:
6,300,143 →
Application:
09/259,347 →
Neutralizing High Affinity Human Monoclonal Antibodies Specific to Rsv F-Protein and Methods for Their Manufacture and Theraputic Use Thereof
Novel Method for Integrating Genes at Specific Sites in Mammalian Cells via Homologous Recombination and Vectors for Accomplishing the Same
Patent:
6,413,777 →
Application:
09/343,485 →
Methods of Treating Autoimmune Diseases with GP39-Specific Antibodies
Patent:
6,440,418 →
Application:
08/925,339 →
New Clinical Parameters for Determining Hematologic Toxicity Prior to Radioimmunotheraphy
Patent:
6,451,284 →
Application:
09/625,856 →
Humanized Antibodies of Human GP39, Compositions Containing and Therapeutic Use Thereof
Patent:
6,506,383 →
Application:
09/332,595 →
Treatment of Psoriasis Using Anti-B7.1(CD80) Antibodies
Patent:
6,709,654 →
Application:
09/383,916 →
Induction of Cytotoxic T-Lymphocyte Responses
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignors Interest.
May 28, 1991
From: RAYCHAUDHURI, SYAMAL
To: IDEC PHARMACEUTICALS CORPORTIONE A CORP. OF CA
Reel/Frame 005712/0290 →
Assignment of Assignors Interest.
Oct 8, 1991
From: RAYCHAUDHURI, SYAMAL; RASTETTER, WILLIAM H.
To: IDEC PHARMACEUTICALS CORPORATION A CORP. OF CALIFORNIA
Reel/Frame 005885/0306 →
Assignment of Assignors Interest.
May 18, 1992
From: NEWMAN, ROLAND A.; HANNA, NABIL; RAAB, RONALD W.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 006134/0307 →
Assignment of Assignors Interest.
Jul 10, 1992
From: NEWMAN, ROLAND A.; HANNA, NABIL; RAAB, RONALD W.
To: IDEC PHARMACEUTICALS CORPORATION, A CA CORP.
Reel/Frame 006227/0606 →
Assignment of Assignors Interest.
May 13, 1993
From: REFF, MITCHELL E.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 006524/0531 →
Assignment of Assignor's Interest
Jan 6, 1995
From: IDEC PHARMACEUTICALS CORPORATION
To: SILICON VALLEY BANK
Reel/Frame 007279/0680 →
Assignment of Assignor's Interest
Jun 7, 1995
From: RAYCHAUDHURI, SYAMAL; RASTETTER, WILLIAM H.; BLACK, AMELIA
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 007771/0032 →
Assignment of Assignor's Interest
Jan 31, 1997
From: ANDERSON, DARRELL R.; HANNA, NABIL; BRAMS, PETER
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 008359/0655 →
Assignment of Assignor's Interest
Sep 18, 1997
From: HANNA, NABIL; BRASLAWSKY, GARY R.; HARIHARAN, KANDASAMY
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 008807/0472 →
Assignment of Assignor's Interest
Jan 8, 1998
From: ANDERSON, DARRELL R.; HANNA, NABIL; BRAMS, PETER; HEARD, CHERYL
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 008910/0466 →
Assignment of Assignor's Interest
Nov 30, 1998
From: COCCIA, MARCO ANTHONY; BRAMS, PETER
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 009675/0082 →
Release of Security Interest
Nov 1, 1999
From: VENTURE LENDING & LEASING, INC.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 010340/0869 →
Assignment of Assignor's Interest
Aug 29, 2001
From: OPLE, ERIC; MCLACHLAN, KAREN; HEARD, CHERYL
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 012125/0883 →
Assignment of Assignor's Interest
Oct 9, 2001
From: REFF, MITCHELL
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 012239/0155 →
Assignment of Assignor's Interest
Nov 5, 2001
From: REFF, MITCHELL
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 012297/0539 →
Assignment of Assignor's Interest
Feb 28, 2003
From: REFF, MITCHELL; BARNETT, RICHARD
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 013812/0526 →
Assignment of Assignor's Interest
Mar 26, 2004
From: BETENBAUGH, MICHAEL J.; FIGUEROA, BRUNO JR.; AILOR, ERIC; HARDWICK, MARIE
To: JOHNS HOPKINS UNIVERSITY
Reel/Frame 014465/0827 →
Assignment of Assignor's Interest
Feb 24, 2005
From: MCLACHLAN, KAREN; GATELY, DENNIS P
To: BIOGEN IDEO INC.
Reel/Frame 015780/0573 →
Release of Security Interest
Jun 27, 2005
From: SILICON VALLEY BANK
To: IDEC PHARMACEUTICALS CORP
Reel/Frame 016735/0591 →
Assignment of Assignor's Interest
Mar 8, 2006
From: BIOGEN IDEC INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 017272/0176 →
Assignment of Assignor's Interest
May 26, 2006
From: BIOGEN IDEC INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 017685/0341 →
Assignment of Assignor's Interest
May 26, 2006
From: MCLACHLAN, KAREN; REFF, MITCHELL; DANIELS, MARK
To: BIOGEN IDEC INC.
Reel/Frame 017685/0323 →
Confirmatory License
May 15, 2008
From: IDEC PHARMACEUTICALS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020950/0588 →
Assignment of Assignor's Interest
Apr 28, 2009
From: BIOGEN IDEC INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 022602/0542 →
Change of Name
Aug 3, 2010
From: IDEC PHARMACEUTICALS CORPORATION
To: BIOGEN IDEC INC.
Reel/Frame 024780/0680 →